RxDoctor Payments Data

Boni Killian-Cobb

Family · Hickory, NCNPI 1255783346

Payments from drug & device makers

$4,575in general payments, 2019–2025

Across 269 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$814
  • GSK$497
  • Novo Nordisk$425
  • Lilly USA, LLC$374
  • AbbVie$370
  • AstraZeneca$234
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$4,575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,575 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$32,769
Medicare patients
92
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$57,439
JardianceEmpagliflozin44$48,630
EliquisApixaban41$43,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$39,215
FarxigaDapagliflozin Propanediol44$36,150
Tresiba Flextouch U-200Insulin Degludec31$23,443
TrulicityDulaglutide15$18,714
MounjaroTirzepatide15$15,432
JanuviaSitagliptin Phosphate16$10,304
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,828
SynthroidLevothyroxine Sodium36$3,218
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,683
Albuterol Sulfate HfaAlbuterol Sulfate72$2,493
Duloxetine Hcl54$2,353
Omeprazole132$1,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$425$57,43931 claims
Boehringer IngelheimJardiance$184$48,63044 claims
GSKTrelegy Ellipta, Anoro Ellipta$497$46,04374 claims
PfizerEliquis$814$43,04941 claims
AstraZenecaFarxiga$234$36,15044 claims
Lilly USA, LLCTrulicity, Mounjaro$374$34,14530 claims
AbbVieSynthroid$370$3,21836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →